Showing 5411-5420 of 5621 results for "".
- Surgeon Age Doesn’t Affect Cataract Surgery Outcomeshttps://modernod.com/news/surgeon-age-doesnt-affect-cataract-surgery-outcomes/2479708/Late-career surgeons perform a large proportion of cataract operations, and they do it with an overall low rate of adverse events, a Canadian study suggests, according to a Reuters report. In recent years, researchers have analyzed
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Ophthotech Expands Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4https://modernod.com/news/ophthotech-expands-retinal-disease-pipeline-with-acquisition-of-versant-ventures-inception-4/2479712/Ophthotech Corporation announced that it has acquired Inception 4, a privately held company backed by Versant Ventures, expanding Ophthotech’s therapeutic pipeline in age-related retinal indications. Through this acquisition, Ophthotech gains worldwide development and commercialization rig
- Mount Sinai Health System Top Presentations and Abstracts From AAOhttps://modernod.com/news/mount-sinai-health-system-top-presentations-and-abstracts-from-aao/2479715/Mount Sinai Health System in New York City made several presentations and poster sessions at the American Academy of Ophthalmology meeting in Chicago. Below is a summary of the abstracts and presentations: “Long-term Efficacy of Fractionated Conformal Radiotherapy for th
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l
- Study: Diabetes Medication May Protect Against AMDhttps://modernod.com/news/study-diabetes-medication-may-protect-against-amd/2479722/Researchers from Taiwan have shown that people with type 2 diabetes who took a common diabetes medication, metformin, had a significantly lower rate of age-related macular degeneration (AMD). The study suggests that the anti-inflammatory and anti-oxidative effects
- New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMDhttps://modernod.com/news/new-stairway-study-data-shows-potential-for-extended-durability-with-faricimab-in-wet-amd/2479728/Genentech announced positive results from the phase 2 STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vi
- Easier, Potentially More Effective Treatment for Blinding Eye Disease Shows Promise in Clinical Trialhttps://modernod.com/news/easier-potentially-more-effective-treatment-for-blinding-eye-disease-shows-promise-in-clinical-trial/2479730/A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections. The researchers involve
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- CheckedUp Announces Expanding Reach in Vision Care and New Product Features at the Point of Carehttps://modernod.com/news/checkedup-announces-expanding-reach-in-vision-care-and-new-product-features-at-the-point-of-care/2479734/CheckedUp announced several new product features to optimize their health care decision technology. With more than 5,000 eye care professionals in the CheckedUp network, the technology empowers patients during their health care journey by engaging and educating them about their care, preventions,